Dynamics of the Cell-Free DNA Methylome of Metastatic Prostate Cancer During Androgen-Targeting Treatment
Lists
Only you see this
Abstract
<b>Aim:</b> We examined methylation changes in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC) during treatment. <b>Patients & methods:</b> Genome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting therapy was performed. <b>Results:</b> Alterations in methylation states of genes previously implicated in prostate cancer progression were observed and patients that maintained methylation changes throughout therapy tended to have a longer time to clinical progression. Importantly, we also report that markers associated with a highly aggressive form of the disease, neuroendocrine-CRPC, were associated with a faster time to clinical progression. <b>Conclusion:</b> Our findings highlight the potential of monitoring the cfDNA methylome during therapy in mCRPC, which may serve as predictive markers of response to androgen-targeting agents.
BibTeX
@inproceedings{peter2020dynamics,
author = {Madonna Peter and Misha Bilenky and Ruth Isserlin and Gary D. Bader and Shu Yi Shen and Daniel D. De Carvalho and Aaron R. Hansen and Pingzhao Hu and Neil Fleshner and Anthony M. Joshua and Martin Hirst and Bharati Bapat},
title = {{Dynamics of the Cell-Free DNA Methylome of Metastatic Prostate Cancer During Androgen-Targeting Treatment}},
booktitle = {Epigenomics},
year = {2020},
doi = {10.2217/epi-2020-0173},
}Loading related content...